CVE-2007-6763
Official description Straight from the sourceThe vendor's or NVD's own wording, published unedited. Authoritative, but often terse — it says what broke, rarely what to do.
NVD · uneditedSAS Drug Development (SDD) before 32DRG02 mishandles logout actions, which allows a user (who was previously logged in) to access resources by pressing a back or forward button in a web browser.
Technical summary Written by usOur analysis, written from the advisory, the CVSS vector and the affected-version data. It adds context the advisory leaves out, and never invents facts that are not in the source.
dbcve analysis · high confidenceSAS Drug Development before version 32DRG02 fails to properly invalidate user sessions upon logout. When a user logs out, the application does not destroy server-side session data or clear authentication tokens, allowing previously authenticated pages to remain accessible via browser back/forward buttons.
Verify against the referenced sources before acting — the references below are authoritative for this CVE, this summary is not.
Affected products & versions What the vendor confirmedThe version ranges the vendor confirmed as vulnerable. If your version sits inside a range here, treat yourself as exposed until you have upgraded.
NVD · CPE data< 32drg02CVSS breakdown How the score is builtThe industry scoring standard. It rates how the flaw is reached, what it takes to exploit, and what an attacker gains — the score is derived from those, not the other way round.
From the vector- Attack vector
- Network
- Complexity
- Low
- Privileges
- Low
- User interaction
- None
- Scope
- Unchanged
- Confidentiality
- High
- Integrity
- High
- Availability
- High
CVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
Am I affected? How to checkSteps we derive from the advisory and the affected-version data, so you can decide whether this CVE reaches your setup. They are a guide, not a scan — your own configuration is the authority.
dbcve checksWork through these to decide whether this CVE applies to you.
-
Identify SAS Drug Development versionLocate the installed version of SAS Drug Development in the application. This is typically found in the application metadata, about page, or version information panel within the product interface. Compare the version number against the affected range (versions prior to 32DRG02).Affected if The installed version is below 32DRG02 (for example, 32drg01, earlier releases, or unpatched installations).
-
Log in to SAS Drug DevelopmentAuthenticate to the SAS Drug Development web interface using valid credentials to establish an authenticated session.Affected if N/A - this step establishes the baseline for subsequent testing.
-
Perform logout actionClick the logout or sign-out option in the SAS Drug Development interface to end the session.Affected if N/A - this step triggers the logout to test session handling.
-
Attempt to access previous page via browser navigationAfter logging out, use the browser back button to navigate to a page that was previously accessible only while authenticated. Alternatively, attempt to access authenticated URLs directly by re-entering them in the browser address bar.Affected if The previously authenticated page loads successfully without requiring re-authentication, indicating the session was not invalidated.
-
Verify session token behaviorInspect browser developer tools (Application/Storage tab) to check if session cookies or authentication tokens associated with SAS Drug Development are still present or still have valid values after logout.Affected if Session cookies or tokens remain intact or are not cleared after performing the logout action.
A system is affected if it runs SAS Drug Development version prior to 32DRG02 AND testing confirms that authenticated pages remain accessible or session tokens persist after logout.
Generated from the published advisory. Verify against your own configuration.
Remediation Closing itWhat it takes to close this. Where a vendor fix exists we point at it; where none exists we say so plainly, and can build one. Effort estimates are scoped from the advisory, not from your codebase.
From vendor data32drg02
Upgrade to SAS Drug Development version 32DRG02 or later, which implements proper session invalidation on logout actions.
- Consultation4.0 h
- Implementation8.0 h
- Testing4.0 h
- Review / QA2.0 h
An estimate, not a bill — we confirm scope with you before any work starts. Need it this week? Rush from $5,120.
Scan for this in your stack
Free · runs locallyCheck whether your project pulls in CVE-2007-6763 — or any other known-vulnerable package — straight from your lock files. Free and open source; it runs locally and uploads nothing.
References Go to the primary sourcePrimary sources — vendor advisories, patches and trackers. Where our summary and a reference disagree, the reference wins.
Primary sourcesPractitioner notes
ContributedPeer-ranked notes from engineers who’ve handled CVE-2007-6763 in production — separate from our analysis above.
The advisory tells you what broke. It rarely tells you what actually worked. If you’ve dealt with this one, that detail is what the next engineer is searching for.
- The version that genuinely resolved it — not the one the vendor claimed
- A config change or rule that shut the vector down
- A gotcha in the upgrade path that cost you an afternoon
No notes yet
Be the first to add a field note for this CVE — a mitigation you’ve verified, a version caveat, or a link to a working fix. Sign in above to contribute.
A place for practitioners to share what actually worked: a mitigation you’ve tested, a configuration change, a version- or environment-specific caveat, or a link to a verified patch. The most useful notes rise to the top as peers upvote them, so the signal stays high.
- Verified mitigations, workarounds, and config changes
- Version or environment caveats, and links to real fixes
- No weaponised exploit code, or anything meant to cause harm
- No spam, self-promotion, credentials, or personal data